Apellis Pharmaceuticals (NASDAQ:APLS) received diverse analyst ratings over the last three months, with 16 analysts offering evaluations. The average 12-month price target is $74.75, with a high of $106.00 and a low of $42.00, marking a 5.28% increase from the previous average of $71.00. Analysts from firms like Oppenheimer, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. It has shown a revenue growth rate of 400.54% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -127.03%, ROE of -48.55%, and ROA of -16.18%.